Arena's S1PR1 agonist meets in Phase II for UC

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS trial to treat ulcerative colitis.

Arena plans to start a Phase III program for the sphingosine 1-phosphate receptor 1

Read the full 370 word article

User Sign In